Mendoza-Morfín F, Montero-González P, Cárdenas-Tirado H, Bravo-Ríos L E
Departamento Clínico de Endocrinología Pediátrica, Hospital General, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México, D.F.
Rev Invest Clin. 1995 Sep-Oct;47(5):371-6.
Fifteen patients with Turner's syndrome with ages between 6.8 to 13.2 years were treated with biosynthetic growth hormone due to their low height. Twelve of them had a 45XO karyotype and three were mosaics; none had a Y line. They started with 0.7 IU/kg/week which were increased to 1.0 IU/kg/week if no height gain was observed during three months. The 15 patients have completed one year of treatment, 8 of them for two years. The height velocity increased significantly (p < 0.001) from 0.24 +/- 0.10 cm/month before treatment (mean +/- SD) to 0.48 +/- 0.09 in the first 12 months of treatment (height increased from 119.1 +/- 8.79 to 124.9 +/- 8.70). In the eight cases who have reached 24 months of treatment, the height velocity increased from 0.27 +/- 0.07 cm/month to 0.47 +/- 0.09 and 0.54 +/- 0.10 at 12 and 24 months respectively (p < 0.001 and p < 0.01 versus the pretreatment gain); height increased from 116.8 +/- 7.0 cm to 122.0 +/- 7.45 and 129.0 +/- 7.18. We found no adverse effects in the patients. It is concluded that the biosynthetic growth hormone treatment in Turner's syndrome can improve low height.
15名年龄在6.8至13.2岁之间的特纳综合征患者因身高较低接受了生物合成生长激素治疗。其中12人核型为45XO,3人为嵌合体;均无Y染色体。开始剂量为0.7IU/kg/周,若三个月内未观察到身高增长,则增至1.0IU/kg/周。这15名患者已完成一年治疗,其中8人治疗了两年。身高增长速度从治疗前的0.24±0.10厘米/月(均值±标准差)显著增加(p<0.001)至治疗的前12个月的0.48±0.09厘米/月(身高从119.1±8.79厘米增至124.9±8.70厘米)。在8例治疗满24个月的患者中,身高增长速度分别在12个月和24个月时从0.27±0.07厘米/月增至0.47±0.09厘米/月和0.54±0.10厘米/月(与治疗前增长速度相比,p<0.001和p<0.01);身高从116.8±7.0厘米增至122.0±7.45厘米和129.0±7.18厘米。我们未发现患者有不良反应。结论是,生物合成生长激素治疗特纳综合征可改善身高偏低的状况。